Cargando…

More Insights into the Association between RVX-208 and Pulmonary Arterial Hypertension

Detalles Bibliográficos
Autores principales:	Ning, Dong, Du, Juan, Yang, Xin-Quan, Wang, Da-Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999104/ https://www.ncbi.nlm.nih.gov/pubmed/31560566 http://dx.doi.org/10.1164/rccm.201908-1628LE

Ejemplares similares

Reply to Ning et al.: More Insights into the Association between RVX-208 and Pulmonary Arterial Hypertension
por: Provencher, Steeve, et al.
Publicado: (2020)

RVX 208
Publicado: (2012)

BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency
por: Lu, Panpan, et al.
Publicado: (2017)

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
por: McLure, Kevin G., et al.
Publicado: (2013)

Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations
por: Wang, Qianqian, et al.
Publicado: (2017)

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
por: Tsujikawa, Laura M., et al.
Publicado: (2019)

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)
por: Wasiak, Sylwia, et al.
Publicado: (2017)

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes
por: Wasiak, Sylwia, et al.
Publicado: (2016)

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro
por: Gilham, Dean, et al.
Publicado: (2021)

BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes
por: Wasiak, Sylwia, et al.
Publicado: (2020)

Can Pulmonary Arterial Compliance Be a Prognostic Marker for Pulmonary Hypertension?
por: Wu, Yanjuan, et al.
Publicado: (2023)

APABETALONE (RVX-208) REDUCES ACE2 PROTEIN ABUNDANCE AND PREVENTS SARS-COV-2 SPIKE PROTEIN BINDING TO HUMAN LUNG CELLS, A MOA THAT COULD ATTENUATE VIRAL ENTRY
por: Fu, Li, et al.
Publicado: (2021)

Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
por: Weatherald, Jason, et al.
Publicado: (2021)

A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension
por: Mohamed, Nura A., et al.
Publicado: (2016)

Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmOnary hyPertension rEgistry (HOPE)
por: Farmakis, Ioannis T., et al.
Publicado: (2022)

BET Bromodomain Inhibitors and Pulmonary Arterial Hypertension: Take Care of the Heart
por: Piquereau, Jérôme, et al.
Publicado: (2019)

CBLN2 rs2217560 was Associated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus
por: Huang, Can, et al.
Publicado: (2018)

Pulmonary Hypertension in Glycogen Storage Disease Type II
por: Li, Hui-Ping, et al.
Publicado: (2018)

Reply to Weatherald et al.: Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
por: Badagliacca, Roberto, et al.
Publicado: (2021)

Prognostic Value of Exercise as Compared to Resting Pulmonary Hypertension in Patients with Normal or Mildly Elevated Pulmonary Arterial Pressure
por: Douschan, Philipp, et al.
Publicado: (2022)

Pulmonary arterial stent for pulmonary trunk stenosis after size-mismatched lung transplantation
por: Xiao, Fei, et al.
Publicado: (2019)

EpiHope for the Treatment of Pulmonary Arterial Hypertension: Selective versus Nonselective BET Inhibition
por: Pullamsetti, Soni Savai, et al.
Publicado: (2019)

Positron Emission Tomography: A Novel Approach to Detect Pulmonary Artery Hypertension at the Early Stage?
por: Tang, Ruidi, et al.
Publicado: (2020)

Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
por: Bogaard, Harm J., et al.
Publicado: (2019)

Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection
por: Zamanian, Roham T., et al.
Publicado: (2020)

Cognitive Dysfunction in Patients with Pulmonary Hypertension
por: Yuan, Ping, et al.
Publicado: (2022)

Effect of COVID-19 in Pulmonary Hypertension
por: Jha, Ajay Kumar
Publicado: (2022)

Targeting the Non-catalytic RVxF Site of Protein Phosphatase-1 With Small Molecules for Ebola Virus Inhibition
por: Lin, Xionghao, et al.
Publicado: (2019)

Patients with Chronic Obstructive Pulmonary Disease Require More Than Pulmonary Rehabilitation to Improve Outcomes
por: Prieto-Centurion, Valentin, et al.
Publicado: (2019)

Reply to Tang et al.: Positron Emission Tomography: A Novel Approach to Detect Pulmonary Artery Hypertension at the Early Stage?
por: Park, Jun-Bean, et al.
Publicado: (2020)

Initial Triple Combination Therapy for Intermediate-and High-Risk Pulmonary Arterial Hypertension: Standard of Care or Still Too Soon to Tell?
por: Jin, Qi, et al.
Publicado: (2021)

Percutaneous pulmonary artery biodegradable stent: a new armament to fight pulmonary artery stenosis?
por: Zou, Hai, et al.
Publicado: (2020)

Diversity of hemodynamic types in connective tissue disease associated pulmonary hypertension: more than a subgroup of pulmonary arterial hypertension
por: Dong, Xingbei, et al.
Publicado: (2022)

Reply to Bogaard et al.: Emphysema Is—at the Most—Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2019)

Pulmonary rehabilitation in long COVID: more than just natural recovery!?
por: Gloeckl, Rainer, et al.
Publicado: (2021)

When more is more: the role of additional upfront therapy in pulmonary arterial hypertension
por: Niedermeyer, Shannon, et al.
Publicado: (2023)

Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?
por: Zheng, Zhenzhen, et al.
Publicado: (2021)

Novel Insight into Pulmonary Fibrosis and Long COVID
por: Kamp, Jan C., et al.
Publicado: (2023)

Competition between Allowed and First-Forbidden $β$ Decay: The Case of $^{208}$Hg$→^{208}$Tl
por: Carroll, R J, et al.
Publicado: (2020)

Increased serum PCSK9 in patients with idiopathic pulmonary arterial hypertension: insights from inflammatory cytokines
por: Zhong, Dong-Xiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_05re0bqh1si9cc0frnld7vfd2i